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Abstract
The technological advancements in genetics produced a profound impact on the research and diagnostics of non-
communicable diseases. The availability of next-generation sequencing (NGS) allowed the identification of novel 
candidate genes but also an in-depth modification of the understanding of the architecture of several endocrine 
diseases. Several different NGS approaches are available allowing the sequencing of several regions of interest or 
the whole exome or genome (WGS, WES or targeted NGS), with highly variable costs, potentials and limitations 
that should be clearly known before designing the experiment. Here, we illustrate the NGS scenario, describe the 
advantages and limitations of the different protocols and review some of the NGS results obtained in different 
endocrine conditions. We finally give insights on the terminology and requirements for the implementation of NGS in 
research and diagnostic labs.
Introduction
The technological advancements in genetics have had 
a profound impact on the research and diagnostics of 
non-communicable diseases. In several of these cases, 
the availability of next-generation sequencing (NGS) 
allowed the identification of novel candidate genes but 
also an in-depth modification of the understanding of the 
architecture of several diseases. Thanks to the power of 
these approaches and the progressive diminution of costs, 
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these changes have been occurring in a short period of time 
and a large portion of clinicians are not prepared for such 
revolution, and misinterpretation of the NGS information 
represents a real danger. This manuscript illustrates the 
new-generation approaches for DNA sequencing and the 
novel scenarios that we are currently facing in order to 
make the clinical endocrinologists aware of the potential 
advantages and risks of this revolution in genetics.
Variable approaches: NGS panel/targeted 
analyses vs WES or WGS
NGS is being adopted by genome diagnostics laboratories 
in different countries worldwide. However, implementing 
NGS-based tests according to diagnostic standards is 
a challenge for individual laboratories (1). One of the 
most important issues that need to be addressed regards 
the selection of the library to be adopted. The main 
question is: ‘Should I make a custom panel for this gene 
set, or should I do whole exome sequencing (WES), or is 
it better to perform whole genome sequencing (WGS)?’ 
The question is crucial since several issues of diagnostic 
or research workflow will depend on this choice (Fig. 1). 
While WGS approach can capture all possible mutations, 
WES or targeted gene panel sequencing (targeted NGS) 
are cost-effective approaches for capturing phenotype-
altering mutations (2, 3). With unlimited resources and 
time, WGS is a clear winner as it allows you to interrogate 
SNVs, insertions or deletions (indels), structural variants 
(SVs) and copy number variants (CNVs) in both the 
1% part of the genome that encodes protein sequences 
and the 99% of remaining non-coding regions. WES is 
focused on the detection of SNVs and indels in protein-
coding genes and on other functional elements such as 
microRNA sequences; consequently, it omits regulatory 
regions such as promoters and enhancers. Although costs 
vary depending on the sequence capture solution, WES 
can be an order of magnitude less expensive than WGS to 
achieve an approximately equivalent breadth of coverage 
of protein-coding exons. These reduced costs offer the 
potential to greatly increase sample numbers, which is 
a key factor for many studies and clinical applications. 
On the other hand, targeted NGS represents the cheaper 
solution adopted in a great number of laboratories 
allowing the optimization of different features of 
molecular diagnostics workflow (reduced costs for library 
preparation steps and sequencing run, adaptable to 
different kind of samples, increased number of samples 
processed in each run and reduction of time needed for 
clinical counselling). In Table 1, we report the potential 
advantages and limitations of those approaches (1, 2, 3, 
4, 5, 6).
Study design for different 
sequencing strategy
The choice of the sequencing strategy should be determined 
by the aim, the underlying biological hypothesis and size 
of the study. The targeted NGS, WES or WGS support the 
different testing strategies, going from the sequencing 
of candidate genes selected for a particular disorder or 
phenotype up to an unsupervised sequencing of all genes 
in the genome.
Studies of population genomics are mainly oriented 
on WGS strategy, they benefit from a trade-off between 
sample numbers and sequencing depth, in which many 
genomes are sequenced at low depth and variants are 
simultaneously called across all samples. Variant calls on 
individual low-depth genomes have a high false-positive 
rate, but this problem is overcome by combining results 
across a high number of samples (7, 8, 9).
When the aim of the study is to identify new genes 
involved in a particular disease, WES usually appears as the 
most convenient choice since it is considerably cheaper 
than WGS and allows the sequencing of a consistent 
number of subjects with a good detection quality of SNVs, 
SVs and indels, but not for CNVs (10, 11).
The analysis of gene panels isolated by targeted capture 
represents a valid alternative for diagnostic applications, 
when the lab should test only causative genes and give 
a response in a short time. The restricted targeting 
represents a relevant advantage as it reduces the possibility 
of incidental findings thus facilitating interpretation of 
genetic results and allowing higher coverage at lower cost 
than genome/exome-wide approaches (Table 1).
Notwithstanding differences among protocols and 
study design, the analytical approach is similar among 
strategies: sequencing step is followed by bioinformatics 
analysis and filtering of genetic variability aimed to 
select genetic variants that are considered clinically 
relevant. In such context, WES and WGS offer the 
advantage of expanding the search space to consider 
additional genes or genomic regions that have not been 
previously identified but that may potentially explain an 
individual’s complex or peculiar clinical presentation. 
However, a single exome can produce approximately 
30 K variants, while more than 3 M variants can be 
found in a single genome. Both in diagnostic and in 
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research areas, the bioinformatics task is fundamental 
but is therefore often long and challenging. Apart from 
the sequencing strategy, the most important challenge 
today is represented by the analysis and classification 
of genomic variants that have not been previously 
reported in the medical literature or in public databases 
(see below). The assessment of the variant pathogenic 
impact should follow accepted guidelines for variant 
classification (1). The classification of genetic variability 
and the determination of its role on human phenotype 
represent one of the most important challenges for 
clinicians, geneticists and researchers.
NGS application for rare or common 
complex diseases
NGS can be applied to study both rare diseases and 
complex diseases. Different examples demonstrate the 
power of NGS in identifying causal variants for rare 
monogenic diseases even with very small sample size 
(12, 13, 14).
However, not all rare conditions reflect the 
scenario of typical monogenic diseases with Mendelian 
inheritance. Indeed, some rare conditions include 
similar manifestations, and the same manifestation can 
Figure 1
Schematic illustration of the algorithm for the choice of the most suitable next-generation sequencing (NGS) approach. Targeted 
NGS is generally more suitable for clinical applications. The whole exome or whole genome sequencing (WES or WGS) approaches 
have mainly research applications, but positive results should expand the targeted NGS approaches. WES can also have a clinical 
application for the diagnosis of particular heritable conditions that are not clinically defined. VUS, variants of uncertain 
significance.
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be induced by different mechanisms. In such context, 
the identification of causal variants generally requires 
larger sample sizes than classic monogenic diseases 
or affected families with multiple generations (15). In 
complex diseases, there is an extreme heterogeneity 
in both the clinical spectrum and underlying 
mechanisms: individuals with similar phenotypes 
may involve different causal variants from the same 
gene or multiple variants in different genes acting 
within the disease pathway(s). Conversely, patients 
with the same causal genetic factor may manifest a 
variable phenotype due to incomplete penetrance, as 
a consequence of the interaction with other genetic, 
epigenetic or environmental modifying factors. In 
this field, the characterization of genetic aetiology can 
become difficult.
A large survey of human genetic variation (16) shows 
that rare variants represent the great part (~70–80%) of 
genetic variability, and the UK10K project identified 
more than 42 M SNVs over 3781 subjects (SNVs, 34.2 M 
rare and 2.2 M low frequency). Statistical genetics 
considerations of rare variant association analysis have 
been the focus of intensive method development over the 
last few years in the field of complex traits studies. Even 
if there is a substantial contribution from rare variants, 
it remains challenging to detect rare variant effects due 
to low statistical power. Deep WGS of large numbers 
of individuals would represent the most informative 
strategy for association studies of complex traits and 
diseases. However, large-scale WGS is generally unfeasible 
in the field of classical epidemiological designs, such 
as case–control and cohort studies, because of the high 
Table 1 Principal applications, advantages and limitations of the three different next-generation sequencing (NGS) strategies.
NGS strategy Principal application Advantages Limitations
Whole genome 
sequencing (WGS)
Studies of population 
genomics
• Identification of SNVs, indels, SV and 
CNVs in coding and non-coding regions
• PCR amplification not required, reducing 
the potential of GC bias
• More consistent and uniform coverage 
compared to WES or Targeted NGS
• A lower average read depth is required 
to achieve the same coverage as WES
• No impact by sequencing read length 
• Performance unaffected by capturing or 
amplification procedures
• Specific protocols of enrichment are not 
required
• Complete information on the genetic 
variability of each sample
• High cost
• Low number of samples
• Huge amount of genetic variants 
identified
• Greater effort in the data 
interpretation
• Limited applications in routine 
diagnostics
Whole exome 
sequencing (WES)
Identification of new 
causative genes
• Identification of SNVs, indels, SV and 
CNVs in coding regions
• Reduction of the cost in comparison with 
WGS
• Reduced number of identified 
genetic variants with a reduction of 
resources needed for their storage and 
interpretation
• Increased number of samples analysed
• More suitable than WGS for clinical 
applications
• Assessment of genetic variability 
only in exons
• Heterogeneous coverage 
influenced by library preparation 
procedures
• High risk of genetic incidental 
findings
Targeted NGS 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of known 
causative genes 
 
 
 
 
 
 
 
 
 
 
 
• Most suitable for clinical applications
• Higher coverage and sequencing depth 
than WES
• Customizable for different samples types, 
e.g. formalin-fixed paraffin-embedded 
tissues, cell free or circulating tumoural 
DNA, degraded samples
• Highest number of samples
• Reduced computational and storage 
resources
• Lower testing costs than WGS and WES
• Genetic variability is determined only for 
selected genes thus reducing the risk of 
incidental findings
• Genetic analysis restricted to 
selected regions
• Variable and heterogeneous 
coverage
• Problematic design of probes
• Biases of library preparation: 
false-positive variants due to PCR 
duplicates or false negative results 
due to allelic drop out
• Difficult identification of CNVs 
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cost. Several less costly sequencing strategies have been 
proposed and used in common traits studies, such as 
low-depth WGS, WES and targeted NGS. Many statistical 
methods have been then proposed to increase the signal 
or reduce the noise in testing variant-disease association 
using sequencing data. These statistical methods can 
be classified into three categories: (i) the BURDEN test 
(17, 18), (ii) the sequence kernel association test (SKAT) 
(19) and (iii) the P values combination methods (20). 
Once a gene/region emerged as significantly associated, 
the next important step is to identify rare causal variants 
within these regions/genes. Identifying a small number 
of rare causal variants that contribute to complex 
diseases has become a major focus of investigation. Each 
of the above gene-based methods reports a P value for 
the association of multiple rare variants and a specific 
phenotypic trait. However, the following identification of 
a small proportion of truly causal variants is an even more 
difficult challenge and often need other approaches such 
as in vitro or in vivo functional studies.
Sequencing errors and confirmation 
of results
More than 200 000 genomes and an even higher number 
of exomes have been sequenced to date. It is still widely 
established that variants found using NGS should be 
validated with the current ‘gold standard’ for DNA 
sequencing, Sanger sequencing (21), though several 
reports suggest that NGS results are at least as accurate 
or in some cases more accurate than Sanger sequencing 
(22, 23). Massively parallel sequencing technologies have 
revolutionized medical genetics, however, also NGS is 
prone to both negative and positive results. Problems may 
be generated during library preparation procedure, PCR 
artefacts for example, can introduce false-positive results 
in capturing-based libraries, while amplicon-based libraries 
are prone to allelic dropout problems due to presence 
of variation in the sequence that produce the selective 
amplification of a single allele. Errors can also be introduced 
during the bioinformatics analysis, extended insertions or 
deletions for example can be missed. To date, there are no 
validated procedures to detect sequencing errors.
NGS for discovery of novel 
pathogenic mechanisms
Conventionally, the diagnostic approach to endocrine 
diseases was based on physical findings, biochemical 
testing and imaging analysis, followed, secondly by 
molecular analysis. Until recently, DNA samples were 
analysed following a phenotype-driven strategy and 
using Sanger sequencing method of the coding regions of 
one candidate gene at a time, an operation that requires 
several weeks for a response.
The scenario has dramatically changed with the 
introduction of NGS. The outcomes, related consequences 
and risks are summarized in Table  2. With the NGS 
introduction, the time needed to systematically sequence 
a set of candidate genes has decreased from several weeks 
to few days. This finally has progressively brought down 
the costs for a massive parallel high-throughput DNA 
sequencing and a comprehensive genetic diagnosis. 
However, this advancement becomes possible with the 
introduction of new key-personnel for the design of NGS 
experiment and bioinformatics data analysis.
An increasing number of scientific reports (>600) 
using NGS for endocrine disease investigations were 
published in peer-reviewed journals since 2009 (Fig.  2). 
Here, we selected some examples showing how NGS 
appeared successful in identifying new causative genes or 
pathogenic mechanisms.
One of these studies is on familial central precocious 
puberty (CPP) (24). The Brazilian authors performed 
a WES in 40 members of 15 families affected by CPP of 
unknown aetiology. NGS analysis identified MKRN3 gene 
as a potential causative candidate gene for the disease. The 
important role of MKRN3 in human puberty initiation was 
reinforced by large genome-wide studies involving women 
of European descent from 57 studies (25). Subsequently, 
several studies confirmed that mutations in the paternally 
expressed imprinted MKRN3 gene constitute a major 
genetic cause of heritable or apparently sporadic CPP 
(26, 27). Very recently, a genomic defect in DLK1, a gene 
encoding a ligand of the Notch receptors, was discovered 
by NGS as being also associated with isolated familial CPP 
(28). Interestingly, MKRN3 and DLK1 are both paternally 
expressed imprinted genes. These findings suggest a role 
of genomic imprinting in regulating the timing of human 
puberty.
Importantly, MKRN3 falls in the locus on chromosome 
15 that is known to be associated with Prader–Willi 
syndrome (characterized by hypothalamic and 
neurological dysfunctions associated with severe obesity 
due to a complete resistance to satiety signals), whereas 
DLK1 had been previously implicated in Temple syndrome 
(including precocious puberty with intrauterine growth 
retardation, postnatal short stature, hypotonia, small 
hands and mild facial dysmorphisms) (28). Therefore, 
Downloaded from Bioscientifica.com at 09/04/2018 03:25:44PM
via free access
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
179:3 R116Review L Persani and others NGS in endocrine diseases
www.eje-online.org
one additional consequence of the NGS approach is the 
unexpected discovery of the association between a single 
gene and two apparently distinct disorders. Another 
example of this kind concerns the JAG1 gene that encodes 
another ligand of the Notch receptors and was originally 
linked to Alagille syndrome (a disorder characterized by 
cholestasis, heart malformations, together with eye, facial 
and skeletal abnormalities, and by an extremely variable 
expressivity and penetrance of the heterozygous JAG1 
mutations) (29). By an NGS approach, we observed that 
monoallelic JAG1 variants are frequently associated with 
rare variants affecting thyroid specific genes in several 
newborns affected with congenital hypothyroidism (CH), 
another disorder characterized by variable expressivity 
and penetrance of the candidate gene defects (30). A 
role for JAG1 in thyroid development was supported by 
in vivo studies in the zebrafish model, and it is therefore 
possible that JAG1 minor alleles could contribute to 
CH pathogenesis by acting as genetic modifiers and 
amplifying the partial loss of function associated with 
monoallelic defects in thyroid-specific genes (31).
Our NGS data obtained in a large Italian cohort of 
CH patients and in an ethnicity-matched population are 
consistent with an oligogenic model of CH pathogenesis 
(30). We found several variants of 11 genes with a 
relevant role in thyroid morphogenesis or function that 
have a rare or low frequency in the general population, 
but a significant enrichment in the CH population. 
When expressed alone in the first-degree relatives of CH 
patients, these rare variants were associated with minor 
Table 2 Novel scenarios opened by the NGS approach offering massive parallel high-throughput DNA sequencing for research 
or diagnosis of endocrine conditions.
NGS aftereffects (ref.) Comments
Reduced time and costs and high accuracy for genetic 
diagnosis (1, 2, 3, 39, 78, 79)
• Novel personnel requirements → bioinformatics for 
experiment planning and interpretation of results
• Potential explanation of patients previously classified as 
phenocopies
Identification of novel causative genes (24, 28, 40, 46, 71, 76) • Expanded understanding of endocrine conditions
• Novel pathogenic mechanisms
Genetic classification of endocrine conditions (44, 50, 51, 52, 
53, 54, 57, 61, 63, 64, 67, 68, 72, 75)
• Precision medicine → targeted therapies and management, 
and accurate prognosis
Identification of multigenic involvement (30, 31, 32, 33, 34, 
38, 41, 42)
• Novel pathogenic mechanisms
• Possible explanation for the variable expressivity and 
penetrance of certain candidate gene variations
Genetic heterogeneity of one condition (34, 36, 38, 42, 43, 44, 
57, 58, 59, 75)
• Expanded understanding of endocrine conditions
• Novel pathogenic mechanisms
• Allelic quantification → more defined prognosis for endocrine 
tumours
One gene associated to multiple clinical conditions  
(26, 28, 29, 31, 37, 38, 40) 
• Role of gene modifiers
• Expanded understanding of gene function 
• Novel pathogenic mechanisms
• Challenging genetic counselling
Defined frequency of gene variants (46, 57, 61, 62, 63, 64, 67, 
68, 77)
• Classification of gene variants
• Improved genetic counselling
Unexpected variants in genes unrelated to the investigated 
condition (incidental findings) (81)
• Ethical issues
• Challenging genetic counselling
• Adequate information for patient’s consent
Identification of variants of unknown significance (78, 79, 80) • Adequate bioinformatic and clinical classification
• Challenging genetic counselling
Figure 2
Timeline of articles in PubMed with the key words: Next-
generation sequencing AND endocrine disease (updated 
March 2018).
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thyroid defects, whereas the variable combinations of ≥2 
minor alleles were unexpectedly found in about 25% of 
CH patients. Other groups obtained similar NGS findings 
in smaller CH cohorts (32, 33). Such an oligogenic origin 
of CH provides a suitable explanation for the frequent 
sporadic appearance of CH in the population. In all these 
NGS studies targeted to a panel of known CH candidate 
genes, the frequency of variations found by their 
systematic and unsupervised analyses was unexpectedly 
higher that the rate of positive findings in previous 
studies performed by Sanger in phenotypically selected 
CH cohorts (5–20% depending upon the investigated 
phenotype). This might be explained both by an increased 
sensitivity of NGS protocols in the genetic variation 
detection as well as by the involvement of morphogenetic 
or functional genes independently of the observed CH 
phenotype. Noteworthy, the number of cases remaining 
unexplained after these targeted NGS analyses falls down 
below 40% thus representing a significant improvement 
for the genetic counselling in clinical practice (34).
In other cases, NGS allowed to link one gene to two 
endocrine conditions that were previously considered 
completely distinct. Izumi et al. identified by NGS a SOX3 
polyalanine deletion in a patient with normosmic isolated 
hypogonadotropic hypogonadism (IHH) (35). This finding 
expanded the phenotypic spectrum of SOX3 polyalanine 
deletion to include IHH without other pituitary hormone 
deficiencies or mental retardation (36). Moreover, they 
detected a WDR11 splice-site mutation in a patient 
with multiple pituitary hormone deficiency (MPHD) 
(35). These data indicate that WDR11, a gene known to 
be involved in normosmic IHH, can also cause MPHDs. 
Similar results had been previously reported for other 
IHH and Kallmann syndrome (KS: IHH with anosmia) 
genes, such as PROKR2 or FGF8 and FGFR1 that have been 
described in MPHDs also (37). The clinical presentation 
of heterozygous defects in candidate genes for IHH/
KS is known to be highly variable among and within 
the same families which, in combination with the >30 
known candidate genes (38), makes the phenotype-driven 
genetic analyses very complicated and expensive, as well 
as disturbing and time consuming for the patients (39). 
The panel of candidate genes was further expanded by an 
NGS study conducted on 261 genes (known to be involved 
in hypothalamic, pituitary, and/or olfactory pathways, or 
suggested by chromosome rearrangements) that identified 
18 new potential candidate genes for IHH/KS (40). In 
such heterogeneous-related conditions (IHH, KS, MPHDs) 
associated with a high number of candidate genes, the 
application of NGS protocols is now unavoidable. Indeed 
the systematic NGS analyses will help to define the exact 
frequency of involvement of single genes and the clinical 
impact of oligogenic involvement (41).
This picture is very similar to that now seen in different 
clinical settings, such as the primary ovarian insufficiency 
(POI) or the disorders of sex development (DSD) (42, 43). 
The genetic diagnosis in POI patients may become useful 
for the preservation of fertility in the affected families or 
in the identification of patients with higher chances to 
obtain a fertilizable egg or at higher risk of extra-ovarian 
defects (44). The Vilain Lab conducted two studies on 
DSD patients (44, 45). In the first, they proposed a novel 
procedure, reversing the order of the diagnostic endocrine 
steps and starting from the genetic analysis. By this 
approach, they claim the possibility to eliminate non-
indicated clinical tests, sparing the patient unnecessary 
stress and saving healthcare system’s resources. They 
designed a targeted panel sequencing of 35 DSD genes 
that revealed genetic defects in two out of seven patients 
not previously diagnosed and confirmed the diagnosis in 
another seven patients with known genetic causes (45). 
In the second study, they performed a WES expanding 
the list of genes to analyse 64 candidates. They reached 
a diagnostic yield of 35% in 40 patients with 46,XY DSD 
who had not previously received a genetic diagnosis (46).
The application of NGS recently expanded the view 
on the mechanisms underlying tumour formation. 
Until recently, activating mutations in the TSH receptor 
(TSHR) and in GNAS represented the principal cause 
of autonomous thyroid adenomas (ATAs) and were 
considered oncogenes sufficient to induce autonomous 
function and growth. In a study conducted on several 
ATAs by WES, we found that a relevant fraction of 
ATAs carry, beyond the well-known TSHR and GNAS 
variants, also a recurrent hot-spot mutation in EZH1, a 
key gene involved in the epigenetic regulation of cell 
differentiation and proliferation. Interestingly, the EZH1 
variant was found to be associated with the TSHR or GNAS 
variants suggesting a 2-hit model for the pathogenesis of 
these benign tumours, whereby constitutive activation of 
the cAMP pathway and EZH1 mutations may cooperate to 
induce the hyperproliferation of thyroid cells (47).
NGS in endocrine tumours: role in 
differential diagnosis and prediction 
of outcome
In the last 10  years, NGS technology led to a better 
knowledge in all human cancers, including endocrine, 
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sporadic and familial tumours. More importantly than in 
other clinical conditions, these new genetic knowledge 
will become more and more useful for clinicians in the 
personalized management of patients.
Cancer is a heterogeneous disease harbouring different 
subclonal cell populations that can be discriminated by 
their DNA mutations. The genome study of a cancer can 
help to better identify its heterogeneity and to support 
the clinicians in the choice of a more effective treatment 
for each patient. For this reason, NGS applications 
are becoming an integral part of the clinical routine 
diagnostics in different endocrine cancers.
In thyroid tumours, NGS represents the gold standard 
technique for the pre-surgical molecular diagnosis of 
thyroid nodules and for the molecular profiling of 
thyroid carcinoma. Fine-needle aspiration cytology is the 
standard pre-operative tool for thyroid nodule diagnosis, 
however, up to 25–30% of the samples are classified as 
indeterminate (48). In these cases, the guidelines of the 
American Thyroid Association recommend molecular 
testing in order to better identify malignant samples and 
to plan patient’s management (49). In order to improve 
diagnosis and optimize the management of thyroid 
nodules with indeterminate cytological diagnosis, 
Nikiforov et al. developed a targeted NGS test, ThyroSeq 
v2, which includes analyses of point mutations, gene 
fusions and abnormal gene expression in 56 thyroid-
related genes (50). Subsequently, various groups validated 
the test (51, 52) that was very recently expanded to include 
112 genes, the ThyroSeq v3 (53). This panel now includes 
also several genes whose role in thyroid carcinogenesis 
remains elusive (e.g. TSHR), thus making indefinite the 
interpretation of several potential variations. However, 
the integration of the genetic and cytology results is 
crucial to allow the stratification of patients according 
to their risk of malignancy, thus enabling an improved 
management (54). The clinical utility of molecular 
testing was demonstrated by the reduction of avoidable 
lobectomies in individuals with indeterminate cytology 
and a benign histological result (50, 55, 56).
Molecular evaluation through NGS techniques 
was also widely performed on histological samples. 
Indeed, new insights were obtained on papillary thyroid 
carcinoma (PTC), the most common type of thyroid 
carcinoma, by the Cancer Genome Atlas network’s study. 
The authors reported a comprehensive genomic landscape 
of 402 PTCs with different NGS technologies, reducing 
the fraction of PTC cases with unknown oncogenic driver 
from 25% to 3.5%. Based on their results, they propose a 
reclassification of thyroid cancers (as BRAF- or RAS-like) 
aimed to improve the management and the therapies of 
the patients (57). An accurate and defined diagnosis is 
needed also for rare and aggressive histotypes, the poorly 
differentiated thyroid carcinoma (PDTC) and anaplastic 
thyroid cancer (ATC): the use of advanced NGS could 
improve the molecular diagnosis of these cancers to 
better clarify their genetic origin and develop new drugs. 
Among the studies performed on the PDTCs and ATCs, 
Landa et  al. examined the largest number of cases (58). 
They applied an ultra-deep sequencing strategy able to 
detect mutations in samples with low tumour purity, 
such as ATCs that are often infiltrated by macrophages, 
and proposed a model of tumorigenesis where PDTCs and 
ATCs derive from well-differentiated tumours through the 
accumulation of additional genetic abnormalities, many 
of which with prognostic and therapeutic relevance. 
Recently, another study focused attention on PDTCs 
(59): Gerber et  al. analysed 25 PDTC cases through the 
Amplicon Cancer Panel (48 specific genes with 212 
amplicons, Illumina). This study identified new potential 
genetic targets in PDTC cases, including for the first time 
four HER4 variants.
Important results were also obtained in medullary 
thyroid carcinoma (MTC), which is mainly caused by 
the RET and, rarely, RAS gene mutations. Many centres 
are implementing the use of NGS technology in MTC 
diagnostic routine, significantly improving the screening 
of familial MTC and the knowledge of somatic alterations 
in order to better plan patients’ management and 
treatments (52, 60, 61, 62). These studies confirmed that 
MTCs had mutually exclusive mutations in RET and RAS 
oncogenes and no other commonly recurrent driver 
mutations were found.
NGS technologies were applied with success also for the 
pheochromocytomas and paraganglioma tumours (PPGL). 
Genetic diagnosis is recommended for all PPGL cases, as 
driver mutations are identified in approximately 80% of 
the cases. The list of genes involved in the pathogenesis 
of PPGL is in constant expansion and targeted NGS has 
proven to be fast and cost-effective also for the genetic 
analysis of PPGL as demonstrated by several studies (63, 
64, 65). Intriguingly, with the application of targeted 
NGS, it was possible to identify pathogenic germline NF1 
mutations in three patients with pheochromocytomas 
without a prior diagnosis of neurofibromatosis type 1 
(NF1) (66).
A relevant advancement has been provided by NGS 
in the study of neuroendocrine tumours (NETs), a very 
heterogeneous neoplastic category. Pancreas NETs (pNET), 
considered biologically more aggressive compared with 
Downloaded from Bioscientifica.com at 09/04/2018 03:25:44PM
via free access
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
179:3 R119Review L Persani and others NGS in endocrine diseases
www.eje-online.org
NET from other sites, are usually sporadic but can also 
occur as part of hereditary syndromes (67, 68). A recent 
study, performed on 90 patients with pNETs by means 
of a custom-targeted NGS panel, characterized the 
genetic signature of each tumour and pointed out the 
importance of a specific gastro-entero-pancreatic targeted 
NGS gene panel. Moreover, these data suggest that the 
MEN1 alterations represent a key event in the malignant 
progression (67). Indeed, germline MEN1 mutations 
have also been reported in five cases of apparently 
sporadic pNETs (with no family history or other MEN1 
tumours) (68).
Key advancements were made by NGS also in several 
other rare endocrine tumours. Some studies analysed 
the complete genomic and transcriptomic landscape of 
primary and recurrent parathyroid tumour specimens 
using high-throughput sequencing technologies; the 
data confirmed the important role of oncogenes CCND1 
and RET, and of tumour suppressors MEN1 and HRPT2, 
but revealed also mutations in well-characterized cancer 
genes such as mTOR, MLL2, CDKN2C, PIK3CA, POT1 
and PRUNE2 (69, 70, 71). Involvement of multiple genes 
were also found in adrenocortical carcinoma (72, 73, 74), 
which may lead to a novel classification (75). The exome 
sequencing of corticotroph adenomas identified somatic 
mutations in the USP8 deubiquitinase gene (76, 77). 
All these data suggest the potential application of 
NGS in defining the pathogenic mechanisms and in 
discovering targets to develop new therapeutics.
Risks associated with research or clinical 
applications of NGS technology
By adopting NGS, clinical laboratories are now 
performing an ever-increasing catalogue of genetic 
testing for genetic disorders. This shift in genetic testing 
has been accompanied by new challenges in sequence 
interpretation. In this context, the American College of 
Medical Genetics and Genomics (ACMG) convened a 
workgroup in 2013 comprised representatives from the 
ACMG, the Association for Molecular Pathology and the 
College of American Pathologists to revisit and revise 
the standards and guidelines for the interpretation of 
sequence variants (1, 78, 79). A mutation was previously 
defined as a rare change in the nucleotide sequence, while 
a polymorphism was defined as a variant with a frequency 
>1%. However, the terms ‘mutation’ and ‘polymorphism’ 
often lead to confusion due to incorrect postulations of 
pathogenic and benign effects, respectively. Thus, the 
ACMG recommends that both terms be replaced by the 
term ‘variant’ with the following modifiers: (a) pathogenic, 
(b) likely pathogenic, (c) uncertain significance (VUS), (d) 
likely benign or (e) benign. While these modifiers may 
not address all human phenotypes, they comprise a 
5-degree system of classification for variants relevant to 
Mendelian disease. It is recommended that all assertions of 
pathogenicity (including ‘likely pathogenic’) be reported 
with respect to a condition and inheritance pattern. Cases 
(a) and (b) include nonsense, frameshift, canonical +/−1 
or 2 splice sites, initiation codon, single exon or multi-
exon deletion. The variants, including the missense ones, 
can also be classified as pathogenic (or likely) based on 
functional studies or by co-segregation with phenotype 
in familial settings, as well as if they appear de novo in 
the index case. The missense variants that do not have 
this support to the potential pathogenic role should be 
classified as VUS. One of the most accurate methods to 
discern the impact of a VUS is the co-segregation studies 
in the affected family. The synonymous or deep intronic 
variations should be classified as likely benign if their 
impact is not supported by functional or inheritance 
studies. Data on the frequency of variants may also be 
relevant for the variant classification, as common variants 
(>1% in the general population) are being generally 
classified as benign.
In silico analyses may be of support in the 
interpretation but the use of multiple databases is 
highly recommended (30, 79). When a variant has been 
identified, a bioinformatics approach should be routinely 
applied (79). Appropriate and dedicated personnel in the 
Lab should certainly check the existing databases for its 
frequency. Population databases (e.g., Exome Aggregation 
Consortium (ExAC)) are useful in obtaining the frequencies 
of variants in large populations. However, these databases 
cannot be assumed to include only healthy individuals, 
as they do not contain extensive information regarding 
any possible associated phenotypes and they can contain 
pathogenic variants. When using population databases, 
one should check whether healthy or disease cohorts were 
used, and if possible, whether more than one individual in 
a family was included, and the age range of the subjects. 
Furthermore, disease- and gene-specific database can be of 
help (e.g., Online Mendelian Inheritance in Man (OMIM) 
or the NCBI), but these databases often contain variants 
that are incorrectly classified (78). The classification of 
an identified variant should also include searching the 
scientific and medical literature.
As an internal method of assessment, clinical 
laboratories should also track all sequence variants 
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identified in each gene together with the related 
clinical questions. This is important for tracking 
genotype–phenotype correlations and the frequency 
of variants in affected and unaffected cohorts and to 
uncover variants with a particular frequency in the 
local population. 
Pitfalls of exome sequencing are always around the 
corner, as in the case of the likely overestimated association 
of HABP2 variant with familial non-medullary thyroid 
cancer. This result may occur despite the development of 
robust computational algorithms, the accrued experience 
of analysing exome data sets and published guidelines. 
The bioinformatics approach thus remains a fundamental 
process with relevant decisions and interpretations that 
require an accurate supervision (80). 
One of the most relevant outcomes of NGS analyses 
is the occasional detection of unexpected variants in 
genes that are totally unrelated to the investigated 
condition, but are associated with clinically occult 
conditions. The incidental finding is obviously possible 
in the NGS protocols not exclusively including the 
disease-specific genes. This gives rise to several ethical 
concerns. It is however not uncommon to find patients 
that although willing to know the cause of an already 
identified condition and refuse to receive predictions 
on the future health risks for their own or other family 
members. Therefore, the consent to NGS analyses should 
contain the possibility to deny the information on these 
off-target results. Notwithstanding, certain incidental 
findings (e.g., the identification of a 100% penetrant 
and strongly pathogenic mutation in RET oncogene 
predisposing to aggressive malignancy) may cause serious 
ethical concerns because disclosing the identification of a 
hereditary cancer predisposition would be highly relevant 
to the clinical care of these patients and have important 
implications for their relatives’ medical management. 
For clinical guidance, we refer the reader to the ACMG 
recommendations (81).
Clinical reports are the final product of laboratory 
testing and are often integrated into the patient’s 
electronic health record. Therefore, effective reports 
should be concise, but easy to understand. Reports 
should be written in clear language avoiding medical 
genetics jargon or defining such terms when used. The 
report should contain all of the essential elements of 
the test performed, including structured results with an 
interpretation, the supporting scientific references, the 
methodology and the appropriate qualifications of the 
personnel.
Conclusions
In the past decade, sequencing technology has evolved 
rapidly with the advent of high-throughput NGS. 
This technology generated a titanic advancement in 
the genomics with the identification of new disease 
mechanisms and the possibility to expand the role of 
predictive and personalized medicine. In this scenario, 
an adequate use of NGS protocols can now give a great 
support to the clinicians in endocrine diseases. For this 
reason, awareness on the advantages and risks of such a 
powerful technology should be further promoted by the 
national health systems.
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